Skip to content

The feasibility study of buccal acupuncture acupoint stimulation combined with remifentanil PCIA for labor analgesia

The feasibility study of cheek acupuncture acupoint stimulation combined with remifentanil PCIA for labor analgesia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002268
Enrollment
Unknown
Registered
2025-11-21
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Remifentanil group:Remifentanil PCIA for labor analgesia
Jiache Acupuncture Points Combined with Remifentanil Group:Stimulation of auricular acupoints combined with remifentanil PCIA for labor analgesia.

Sponsors

Nanchang University First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-40 years, singleton pregnancy, term pregnancy (37-42 weeks); (2) No pregnancy complications (e.g., hypertension, diabetes, placenta previa, etc.); (3) No obstetric contraindications (e.g., abnormal fetal presentation, fetal distress in utero, etc.); (4) No history of allergy to anesthetic drugs; (5) Voluntary signing of informed consent; (6) No history of mental illness or substance abuse; (7) Enrollment begins during the active phase of labor (cervical dilation =4 cm).

Exclusion criteria

Exclusion criteria: (1) Severe dysfunction of heart, liver, or kidney; (2) Coagulation disorders or currently using anticoagulant medications; (3) Severe respiratory system diseases; (4) Mental disorders or cognitive impairments; (5) Contraindications for acupuncture (e.g., skin infections, bleeding tendencies, etc.); (6) History of adverse delivery outcomes (e.g., difficult labor, postpartum infections, etc.); (7) The mother refuses the use of buccal needle acupoint stimulation; (8) Abnormal progress of labor (e.g., labor arrest); (9) History of substance abuse.

Design outcomes

Primary

MeasureTime frame
Remifentanil consumption;

Secondary

MeasureTime frame
Pain Score;Maternal satisfaction;

Countries

China

Contacts

Public ContactWen Ting

Nanchang University Affiliated First Hospital

wenting.nc@outlook.com13803542629

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026